Date issuedProductSafety information
5/7/2019 blinatumomab

​Blincyto (pembrolizumab): Risk of Medication Errors and Benzyl alcohol toxicity​.CLICK HERE​

4/29/2019 Genvoya ® (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide)

Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection due to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy.CLICK HERE​​​

4/15/2019 Dapagliflozin

Risk of Fournier’s gangrene (necrotising fasciitis of the perineum) with Sodium-glucose-Co-Transporter 2 inhibitors (SGLT2i).CLICK HERE​​

4/11/2019 Tocilizumab

Actemra® (tocilizumab): A New Important Identified Risk: Hepatotoxicity.CLICK HERE​​​

4/4/2019 Adenuric® (Febuxostat)

Febuxostat (adenuric®): Higher rate of cardiovascular death in gout patients with established cardiovascular disease.CLICK HERE​​​

3/25/2019 Belimumab

Benlysta (Belimumab) and Risk of serious Depression and/ or Suicidal ideation or Behavior or self-injury.CLICK HERE​

2/26/2019 Atezolizumab

​TECENTRIQ® (atezolizumab): A New Important Identified Risk: Immune-related Myositis. CLICK HERE​​

2/4/2019 Canagliflozin

Risk of Fournier´s gangrene (necrotising fasciitis of the perineum) with Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i).CLICK HERE​

1/22/2019 Pembrolizumab

Keytruda (pembrolizumab): Restriction of indication for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy.CLICK HERE​

12/16/2018 Empagliflozin

Direct Healthcare Professional Communication on the association of Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i) with Risk of Fournier´s gangrene (necrotising fasciitis of the perineum). CLICK HERE​​